Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NeoDC-Vac + ICIs Maintenance for Esophageal Squamous Cell Carcinoma
NCT06675201Phase 2Recruiting
- Sponsor
- Sichuan University
- Start
- Oct 2024
- Primary completion
- Oct 2027
- Modality
- Whole Cell Cancer Vaccines, Dendritic Cell Vaccines
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of NeoDC-Vac in Esophageal Squamous Cell Carcinoma (ESCC) (2 arms), sponsored by Sichuan University. Primary endpoint: 2-year Overall Survival Rate. Started Oct 2024; status: recruiting.
02
Drugs
NeoDC-Vac
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on NCT06675201.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06675201.